SOMATOSTATIN RECEPTOR-POSITIVE NEUROENDOCRINE TUMOR
Clinical trials for SOMATOSTATIN RECEPTOR-POSITIVE NEUROENDOCRINE TUMOR explained in plain language.
Never miss a new study
Get alerted when new SOMATOSTATIN RECEPTOR-POSITIVE NEUROENDOCRINE TUMOR trials appear
Sign up with your email to follow new studies for SOMATOSTATIN RECEPTOR-POSITIVE NEUROENDOCRINE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New imaging trick could tame radioactive cancer therapy
Knowledge-focused CompletedThis completed Phase 1 study tested whether a PET scan using 64Cu-DOTATATE (Detectnet) can help doctors plan safer doses of Lutathera therapy for people with neuroendocrine tumors. Four participants received both standard Lutathera treatment and extra PET/CT and SPECT/CT scans to…
Matched conditions: SOMATOSTATIN RECEPTOR-POSITIVE NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
LUTATHERA safety checked in 347 patients after market approval
Knowledge-focused CompletedThis study looked at the real-world safety of LUTATHERA, a radioactive drug used to treat a type of nerve and hormone cell cancer called neuroendocrine tumors. Researchers tracked 347 patients who received the drug in regular medical practice, focusing on kidney problems, bone ma…
Matched conditions: SOMATOSTATIN RECEPTOR-POSITIVE NEUROENDOCRINE TUMOR
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC